.svg){kind=small}
Oct-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Avexia has demonstrated a consistent performance in the Illinois market, particularly in the Topical category, where it has maintained the number one rank from July to October 2025. This stability indicates a strong foothold in this category, despite a slight decrease in sales from September to October. In the Capsules category, Avexia also held a steady second position, though sales showed a downward trend over the months. On the other hand, the brand's ranking in the Concentrates category experienced a decline, moving from 15th to 24th position by October, reflecting possible challenges in maintaining competitiveness in this segment.
In Maryland, Avexia's performance in the Capsules category saw a slight dip in rank, moving from second to third place by October, accompanied by a decrease in sales figures. Conversely, in the Concentrates category, they showed a stable rank, maintaining around the 19th and 20th positions, with an encouraging upward trend in sales. The Topical category in New Jersey revealed a strong presence, consistently ranking first or second, although sales fluctuated across the months. Notably, Avexia did not maintain a top 30 presence in the Concentrates category in Ohio by October, which could be a point of concern. However, the brand's consistent third position in the Tincture & Sublingual category in Ohio indicates a stable market segment for Avexia.
Competitive Landscape
In the Illinois Topical category, Avexia has consistently maintained its top position from July to October 2025, indicating strong brand loyalty and market presence. This stability in rank is particularly impressive given the fluctuations seen among competitors. For instance, Doctor Solomon's has held the second position throughout the same period, yet its sales have shown a downward trend, especially noticeable in September 2025. Meanwhile, Pheotera Grove experienced a rank drop in August, indicating they were not in the top 20 that month, but rebounded to fourth place by October, suggesting a potential resurgence. These dynamics highlight Avexia's robust market strategy and product appeal, which have allowed it to outperform competitors consistently, securing its leadership in the Illinois Topical market.
Notable Products
In October 2025, the top-performing product from Avexia was the CBD/THC 1:1 Harmony Pain Relief Balm in the Topical category, maintaining its consistent first-place ranking since July with sales of 8,436 units. The CBD/THC 4:1 Relief Tablets in the Capsules category held steady in second place, showing a slight decline in sales over the months. The CBN/CBD/THC 1:1:1 Comfort Tablets also remained in third place, continuing its downward sales trend from July through October. Meanwhile, the CBD/THC 1:1 Harmony Micro-Dosed Tablets and CBG/THC 1:1 Ascend Tablets retained their fourth and fifth positions, respectively, with both experiencing a gradual decrease in sales. Overall, the rankings of Avexia's top products have remained unchanged since July, although there has been a noticeable decline in sales figures across the board.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
